Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | DEPTOR | Q8TB45 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486657 | 0.97 | IDO1 (0.50) | IDO1TSHRMAPTALDH1A1LMNA | |
| Water SCHEMBL29052961 | 0.94 | IDO1 (0.48) | IDO1TSHRMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7413150 | 0.83 | RAPGEF4 (0.45) | IDO1MAPTALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL670927 | 0.83 | RAPGEF4 (0.47) | IDO1ALDH1A1RAPGEF4CYP1A2CYP2C9 | |
| SCHEMBL18706950 | 0.79 | IDO1 (0.38) | IDO1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL360242 | 0.79 | RAPGEF4 (0.48) | IDO1ALDH1A1RAPGEF4CYP1A2CYP2C9 | |
| SCHEMBL11942143 | 0.79 | IDO1 (0.42) | IDO1TSHRMAPTALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL4376336 | 0.78 | RAPGEF4 (0.51) | IDO1MAPTALDH1A1CYP3A4RAPGEF4 | |
| Hydrochloric Acid SCHEMBL20984783 | 0.78 | ALDH1A1 (0.39) | IDO1MAPTALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL15110958 | 0.74 | ALDH1A1 (0.43) | IDO1TSHRMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| US-12435068-B2 | Anthelmintic compounds | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4577206-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | Celmatix Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-119409690-A | Novel insect repellent compound | 拜耳动物保健有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240425464-A1 | Substituted Monohydrazides as Potent Antifungal Agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| EP-0483881-A1 | 3-Amidoindolyl derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| CN-1015983-B | Process for preparing gametocides pyrazoles | LILLY CO ELI (US) | 1992-03-25 | — | — | CN | disclosed |
| WO-1991016307-A1 | 3-INDOLYL THIOACETATE DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-31 | — | — | WO | disclosed |
| US-5051442-A | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-24 | — | — | US | disclosed |
| CN-87102443-A | Cametocidal pyrazoles | — | 1987-10-14 | — | — | CN | disclosed |
| US-4343812-A | Antidepressant 2-amino-and-2-(substituted amino)-cis-hexahydro-carbazoles, compositions and use | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| EP-0004342-B1 | CARBAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND INTERMEDIATES THERETO | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-07-15 | — | — | EP | disclosed |
| US-4254134-A | Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles | ENDO LABORATORIES, INC. (US) | 1981-03-03 | — | — | US | disclosed |
| EP-0004342-A1 | Carbazoles, process for their preparation, pharmaceutical compositions containing them, and intermediates thereto | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | GAA 3429/4885PTGS2 2868/4885IDO1 3504/4885 |
| US-20240425464-A1 | Substituted Monohydrazides as Potent Antifungal Agents | ERG28, DPM1, MANBA | GAA 49/4885PTGS2 4475/4885IDO1 663/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | GAA 3693/4885PTGS2 416/4885IDO1 403/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | GAA 4537/4885PTGS2 4496/4885IDO1 4292/4885 |
| US-12435068-B2 | Anthelmintic compounds | H1-10, HRH2, HRH1 | GAA 818/4885PTGS2 501/4885IDO1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.